Bridgeway Capital Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Bridgeway Capital Management’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-52,900	Closed	-$51K	–	1539
2018 Q3	$51K	Buy	+52,900	New	+$88.5K	﹤0.01%	1411
2016 Q4	–	Sell	-2,900	Closed	-$18K	–	1498
2016 Q3	$18K	Hold	2,900	–	–	﹤0.01%	1416
2016 Q2	$13K	Sell	2,900 -48,846	-94%	-$319K	﹤0.01%	1422
2016 Q1	$543K	Buy	51,746 +28,000	+118%	+$556K	0.01%	1011
2015 Q4	$701K	Buy	23,746 +360	+2%	+$10.9K	0.01%	914
2015 Q3	$739K	Buy	23,386 +20,500	+710%	+$981K	0.02%	859
2015 Q2	$171K	Hold	2,886	–	–	﹤0.01%	1376
2015 Q1	$308K	Sell	2,886 -40	-1%	-$3.81K	0.01%	1254
2014 Q4	$275K	Buy	2,926 +320	+12%	+$30.5K	0.01%	1242
2014 Q3	$200K	Buy	+2,606	New	+$205K	0.01%	1339
2013 Q4	–	Sell	-11,480	Closed	-$312K	–	1474
2013 Q3	$312K	Buy	11,480 +2,195	+24%	+$70.6K	0.01%	1221
2013 Q2	$335K	Buy	+9,285	New	+$348K	0.01%	1127

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

MFGP

Marshall Financial Group (Pennsylvania) Doylestown, Pennsylvania $364M AUM 12.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridgeway Capital Management's PTX Position: Q4 2018 in Review

Bridgeway Capital Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q4 2018, closing a stake of 52,900 shares — an estimated $51K sold.

Bridgeway Capital Management first reported a position in PTX in Q2 2013 and held it in 12 quarters. The position peaked at $739K in Q3 2015. 32 funds tracked by Wall St. Rank hold PTX as of Q4 2018.

Bridgeway Capital Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q4 2018 after selling out during the quarter.
Bridgeway Capital Management sold 52,900 Pernix Therapeutics Holdings, Inc. shares in Q4 2018, an estimated $51K.
Bridgeway Capital Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2013 and held it in 12 quarters.
Bridgeway Capital Management's Pernix Therapeutics Holdings, Inc. position peaked at $739K in Q3 2015.
32 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2018.

Based on Bridgeway Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.